1. Pembrolizumab versus ipilimumab in advanced melanoma (keynote-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert,2019
2. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): a randomised, controlled, phase 2 trial;Ribas,2015
3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-ctla-4 treatment (checkmate 037): a randomised, controlled, open-label, phase 3 trial;Weber,2015
4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert,2014
5. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok,2017